The median overall survival rate for patients with a tumour harbouring APC/CTNNB1/ZNRF3 alteration was significantly lower compared to the ones without (43 vs 114 months, log rank p = 0.0141, Fig. 5a). This evidence concerns the gene ZNRF3 and neoplasm.